Prostate cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 20, Issue SUPPL. 4, 2009, Pages

  Horwich, A ^a   Parker, C ^a   Kataja, V ^b,c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b VAASA CENTRAL HOSPITAL   (Finland)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN; BICALUTAMIDE; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DOCETAXEL; ESTROGEN; GONADORELIN AGONIST; PROSTATE SPECIFIC ANTIGEN; STRONTIUM 89;

ARTICLE; BONE METASTASIS; BONE PAIN; BRACHYTHERAPY; CANCER HORMONE THERAPY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED RADIOTHERAPY; DIGITAL RECTAL EXAMINATION; ERECTILE DYSFUNCTION; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; GYNECOMASTIA; HUMAN; METASTASIS POTENTIAL; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; PROSTHESIS; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RISK ASSESSMENT; URINE INCONTINENCE; WATCHFUL WAITING;

EUROPE; FOLLOW-UP STUDIES; HEALTH PLANNING GUIDELINES; HUMANS; MALE; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 66549113359     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp135     Document Type: Article

References (24)

1. Schröder FH, Hugosson J, Roobol MJ et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 13: 360.
2. Andriole GL, Grupp RL III, Buys SS et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 13: 360.
3. Thompson IM et al. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006; 98: 529-534.
4. Gleave ME, Coupland D, Drachenberg D et al. Ability of serum prostate-specific antigen levels to predict normal bone scans in patients with newly diagnosed prostate cancer. Urology 1996; 47: 708-712.
5. O'Sullivan J et al. Broadening the criteria for avoiding staging bone scans in prostate cancer: A retrospective study of patients at the Royal Marsden Hospital. BJU Int 2003; 92: 685-689.
6. Partin AW et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843-848.
7. Lu Yao GL, Yao SL. Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997; 349: 906-910.
8. Bill-Axelson A et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005; 352: 1977-1984.
9. Steineck G. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790-796.
10. Klotz L. Active surveillance with selective delayed intervention: Using natural history to guide treatment in good risk prostate cancer. J Urol 2004; 172(5 Pt 2): S48-S51.
11. Dearnaley DP et al. Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005; 92: 488-498.
12. Dearnaley DP et al. Escalated dose versus standard dose conformal radiotherapy in prostate cancer: First results from the MRC RT01 randomised controlled trial. Lancet Oncol 2007; 8: 475-487.
13. Bolla M et al. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578.
14. Lawton CA, Winter K, Murray K et al. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937-946.
15. Pilepich MV, Winter K, John MJ et al. Phase III Radiation Therapy Oncology Group (RTOG) trial 86-10 of androgen deprivation adjunct to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 50: 1243-1252.
16. D'Amico et al. 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: A randomized controlled trial. JAMA 2004; 292: 821-827.
17. Denham JW et al. Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 2005; 6: 841-850.
18. Widmark A et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61: 145-151.
19. Tannock IF, de Witt R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
20. Petrylak DP, Tangen C, Hussain M et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
21. Porter AT et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993; 25: 805-813.
22. Quilty P et al. A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 1994; 31: 33-40.
23. Saad F et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
24. Autier et al. Cancer survival statistics should be viewed with caution. Lancet Oncol 2007; 8: 1050-1052.